Thus, the preventive effect of SGLT2 inhibitors on SCD, if any, may be more prominent in high-risk populations such as patients with heart failure, ischemic heart disease, and cardiomyopathy. Here, SLC5A2 is linked to Schnyder corneal dystrophy.